J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoneda, H.
Right arrow Articles by Shirai, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoneda, H.
Right arrow Articles by Shirai, M.
Agricola
Right arrow Articles by Yoneda, H.
Right arrow Articles by Shirai, M.
J Med Microbiol 52 (2003), 409-415; DOI: 10.1099/jmm.0.04992-0
© 2003 Society for General Microbiology
ISSN 0022-2615

Aspirin inhibits Chlamydia pneumoniae-induced NF-{kappa}B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth

Hiroshi Yoneda1,2, Koshiro Miura1,4, Hiroshi Matsushima1,3, Kazuro Sugi4, Tomoyuki Murakami4, Kazunobu Ouchi5,{dagger}, Katsuhiro Yamashita2,{ddagger}, Haruhide Itoh2,§, Teruko Nakazawa1, Michiyasu Suzuki2 and Mutsunori Shirai1

1–3Departments of Microbiology1, Neurosurgery2 and Pediatrics3, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan 4Department of Clinical Research, National Sanyo Hospital, Ube, Yamaguchi, 755-0241, Japan 5Saiseikai General Hospital, Shimonoseki, Yamaguchi, 751-0823, Japan

Correspondence Mutsunori Shirai mshirai{at}po.cc.yamaguchi-u.ac.jp

Received June 11, 2002
Accepted December 11, 2002


    Abstract
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Infection with Chlamydia pneumoniae has been implicated as a potential risk factor for atherosclerosis. This study was designed to investigate the mechanisms of the anti-chlamydial activity of aspirin. A reporter gene assay for NF-{kappa}B activity, immunoblot analysis for cyclo-oxygenase (COX)-2 and radioimmunoassay for prostaglandin E2 (PGE2) were performed. Following infection of HEp-2 cells with C. pneumoniae, NF-{kappa}B was activated, COX-2 was induced and PGE2 was elevated. Aspirin inhibited NF-{kappa}B activation at a concentration of 0.1 mM, partially inhibited COX-2 induction and blocked PGE2 synthesis completely. In addition, high doses of aspirin (1 and 2 mM) inhibited chlamydial growth in HEp-2 cells, decreasing the number and size of inclusion bodies; this effect could be overcome by adding tryptophan to the culture. Indomethacin also blocked the synthesis of PGE2, but had no effect on COX-2 expression or chlamydial growth. These results indicate that aspirin not only has an anti-inflammatory activity through prevention of NF-{kappa}B activation but also has anti-chlamydial activity at high doses, possibly through depletion of tryptophan in HEp-2 cells.


{dagger}Present address: Department of Pediatrics II, Kawasaki Medical School, Kurashiki, Okayama, 701-0192, Japan.

{ddagger}Present address: Yamaguchi Rosai Hospital, Onoda, Yamaguchi, 756-0803, Japan.

§Present address: Neurosurgery, Shimonoseki National Hospital, Shimonoseki, Yamaguchi, 751-0823, Japan.

Abbreviations: COX, cyclo-oxygenase; PGE2, prostaglandin E2.


    INTRODUCTION
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Chlamydia pneumoniae, a Gram-negative obligate intracellular bacterium, is known to be a respiratory pathogen (Grayston, 1992; Grayston et al., 1986, 1990). This micro-organism can cause chronic infection and has recently been linked to atherosclerotic disease. Since Saikku et al. (1988) first reported serological evidence of an association between C. pneumoniae and coronary heart disease, a number of serological investigations have shown a positive relationship between C. pneumoniae infection and cardiovascular and cerebrovascular diseases (Cook et al., 1998; Miyashita et al., 1998; Wimmer et al., 1996), such as carotid atherosclerosis (Melnick et al., 1993). Furthermore, C. pneumoniae has been detected in atherosclerotic but not normal arteries by several techniques (Kuo et al., 1993; Ouchi et al., 1998; Shor et al., 1992; Yamashita et al., 1998) and isolated from coronary (Ramirez, 1996) and carotid (Jackson et al., 1997) atheromas. These findings suggest that chronic C. pneumoniae infection might be a trigger and/or enhancer of inflammatory reactions in the vessel wall and thus a causative agent of atherosclerosis.

Several lines of evidence indicate that the dimeric transcription factor NF-{kappa}B plays an important role in atherosclerosis (Brand et al., 1996; Collins, 1993; Dichtl et al., 1999; Gawaz et al., 1998; Ross, 1993). NF-{kappa}B controls the expression of various genes involved in inflammation and proliferation, such as intercellular adhesion molecule-1 (ICAM-1) (Baeuerle & Henkel, 1994; Dichtl et al., 1999; Poston et al., 1992), vascular cell adhesion molecule-1 (VCAM-1) (Cybulsky & Gimbrone, 1991; Dichtl et al., 1999; Neish et al., 1992), cyclo-oxygenase-2 (COX-2) (Appleby et al., 1994; D'Acquisto et al., 1997; Pistritto et al., 1999) and inducible nitric oxide synthase (iNOS) (Chu et al., 1998; Marks-Konczalik et al., 1998). In its inactive state, the prototypic NF-{kappa}B dimer, consisting of subunits p50 and p65 (Rel A), is present in the cytoplasm bound to an inhibitory protein, I{kappa}B (Baeuerle & Baltimore, 1988). NF-{kappa}B is activated to translocate to the nucleus after degradation of I{kappa}B (Traenckner et al., 1994) in response to a number of stimuli including inflammatory cytokines (Baeuerle & Henkel, 1994; Marks-Konczalik et al., 1998), pathogenic micro-organisms (Krull et al., 1999; Sharma et al., 1998; Speir et al., 1998) and bacterial LPS (Kol et al., 1999; Pistritto et al., 1999).

Acetyl salicylic acid (aspirin), widely used to treat inflammation, can specifically inhibit the activation of NF-{kappa}B through binding to I{kappa}B kinase-ß (IKKß), an enzyme that phosphorylates I{kappa}B, leading to its degradation (Kopp & Ghosh, 1994; Yin et al., 1998). Recent experiments have shown that aspirin inhibits cytomegalovirus-induced NF-{kappa}B activation and prevents replication of the virus (Speir et al., 1998). In addition, aspirin and another non-steroidal anti-inflammatory drug, indomethacin, inhibit COX-2 activity and so block the formation of prostaglandins (Gierse et al., 1999). Recently, it has been demonstrated that C. pneumoniae infection in endothelial cells triggered activation of NF-{kappa}B, induced phosphorylation of p42/p44 MAPK and induced the expression of adhesion molecules such as ICAM-1, VCAM-1 and endothelial-leukocyte adhesion molecule-1 (E-Selectin). This was followed by subsequent rolling, adhesion and migration of leukocytes (Krull et al., 1999).

In the present study, we have demonstrated the effect of aspirin on chlamydial growth and activation pathways of NF-{kappa}B, COX-2 and prostaglandin E2 (PGE2).


    METHODS
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell culture.

HEp-2 (ATCC CCL-23), a human epithelioid larynx carcinoma-derived cell line, was maintained in Iscove's modified Dulbecco's medium (IMDM; Gibco-BRL) supplemented with 10 % heat-inactivated fetal calf serum (FCS; PAA Laboratories), 100 µg ampicillin ml-1 and 50 µg gentamicin ml-1. Cells pre-cultured at 37 °C with 5 % CO2 in 75 or 25 ml culture flasks (Sumilon) were allowed to adhere to tissue-culture plates (Sumilon) prior to use.

Chlamydial strain.

C. pneumoniae strain J138, isolated in Japan in 1994 (Shirai et al., 2000), was grown in HEp-2 cells and elementary bodies (EBs) were purified by discontinuous centrifugation in urografin (Caldwell et al., 1981). EBs, diluted with a sucrose/phosphate/glutamate buffer supplemented with 10 % FCS, were stored at -80 °C until use. Titration was performed and titres were expressed as inclusion-forming units (i.f.u.) ml-1.

Inoculation of C. pneumoniae.

The stock chlamydial suspension was thawed and diluted in IMDM. For the growth assay, HEp-2 cells (5 x 104 per well) grown in IMDM in 96-well tissue-culture plates for 24 h received 1.5 x 103 i.f.u. per well, resulting in an m.o.i. of 0.03. For other experiments, cells grown in 24-well plates received 2.0 x 105 i.f.u. per well, while cells grown in 6-well plates received 8.0 x 105 i.f.u. per well, resulting in an m.o.i. of 0.4 in each case. The inoculum was centrifuged at 700 g for 1 h at 22 °C followed by incubation at 36 °C for a further hour. After the extracellular bacteria were removed, infected cells were further incubated in IMDM with or without aspirin (acetyl salicylic acid) or indomethacin (1-[p-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid) (Sigma) at the concentrations indicated. The concentrations of drugs used in this study were similar to those used in a previous analysis (Yin et al., 1998). Non-infected cells were treated similarly with the drugs.

NF-{kappa}B reporter gene assay.

Plasmid pNF{kappa}B-Luc, carrying five NF-{kappa}B DNA-binding sites driving the expression of the luciferase gene, and plasmid pCMVß, carrying the ß-galactosidase gene (Siebenlist et al., 1994), were purchased from Stratagene. HEp-2 cells (2 x 105) grown in 24-well plates for 24 h were co-transfected with 600 ng of the reporter plasmid pNF{kappa}B-Luc and 60 ng of the control plasmid pCMVß using the Trans IT-LT polyamine transfection reagent (Mirus) (Budker et al., 1996; Gupta et al., 1996) followed by incubation for 20 h. The transfected cells were infected with C. pneumoniae at an m.o.i. of 0.4. At the indicated time-points (0, 8, 24 and 48 h), cells were washed with PBS and lysed in 150 µl lysis buffer (Pica Gene). The cell extracts were assayed for luciferase in a luminometer (Microlumat Lb 96P; Berthold) and for ß-galactosidase after heat-inactivation of endogenous ß-galactosidase (Shaper et al., 1994). Relative luciferase activity was defined as the mean ± SD (n=5) of the activity ratio of luciferase/ß-gal. TNF-{alpha} was purchased from Genzyme.

Immunoblot analysis of cyclo-oxygenase.

HEp-2 cells were grown in 6-well plates, infected with C. pneumoniae and then treated with drugs. At the indicated time-points, cells were washed with cold PBS, harvested and lysed in SDS sample buffer (62.5 mM Tris/HCl, pH 6.8, 2 % SDS, 10 % glycerol, 5 % ß-mercaptoethanol, 0.1 % bromophenol blue). Samples were sonicated three times for 5 s each in a cold-water bath with a sonicator (Bioruptor; Cosmo Bio) and heated to 100 °C for 5 min. Samples, containing 20 µg protein, were electrophoresed in 10 % SDS-polyacrylamide gels and separated proteins were transferred on to a nitrocellulose membrane. The membrane was blocked for 3 h with 5 % non-fat dried milk in Tris-buffered saline with 0.1 % Tween 20 at room temperature and incubated overnight at 4 °C with rabbit polyclonal IgG anti-COX-2 or anti-COX-1 antibodies (Santa Cruz Biotechnology). The appropriate secondary horseradish peroxidase-conjugated antibody (Amersham Pharmacia Biotech) was added and complexes were detected by enhanced chemiluminescence (Amersham Pharmacia Biotech).

Determination of PGE2.

HEp-2 cells were grown in 24-well plates and infected with C. pneumoniae (2.0 x 105 i.f.u. per well). At the indicated time-points, PGE2 levels in culture supernatants were measured using a PGE2125I radioimmunoassay (BIOTRAI; Amersham Pharmacia Biotech) as described in the manufacturer's instruction manual.

Determination of NO.

NO (nitrite plus nitrate) was determined using an HPLC NO-detector system (ENO-20; Eicom Co.). Aliquots of 10 µl culture supernatant, after centrifugation at 1000 g for 1 min, were injected into the HPLC system, consisting of an ion-exchange column to separate nitrite and nitrate and a cadmium-reduction column to reduce nitrate to nitrite. Total nitrite was mixed with Griess reagent and the A540 was measured using a flow-through spectrophotometer.

Growth of C. pneumoniae.

Growth of C. pneumoniae was determined by counting inclusion bodies. After the infection was established, the inoculum was replaced with IMDM with or without aspirin or indomethacin and incubated further for up to 48 h at 36 °C. The cells were fixed, stained and examined under a fluorescence microscope at a magnification of x200 for the presence of inclusion bodies. Immunofluorescence staining of C. pneumoniae was performed with the C. pneumoniae-specific mAb RR402 (Washington Research), as described previously (Matsushima et al., 1999). Numbers of i.f.u. were determined on the basis of the mean number of inclusion bodies per field determined in five fields per well from five samples. Relative chlamydial growth (%) was calculated as 100 x (i.f.u. of treated sample/i.f.u. of untreated control). L-Tryptophan was purchased from Sigma.

Statistical analysis.

Statistical comparisons were made using the Mann–Whitney U test for the growth assay and Student's unpaired t-test for the other experiments. Values of P < 0.05 were considered significant.


    RESULTS
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Inhibition of C. pneumoniae-induced NF-{kappa}B activation by aspirin

NF-{kappa}B activation in C. pneumoniae-infected HEp-2 cells was measured by NF-{kappa}B reporter gene assay (Fig. 1). NF-{kappa}B activity (indicated as relative luciferase activity) was increased at 8 and 24 h post-infection and decreased to non-infected levels after 48 h. Conversely, TNF-{alpha} treatment of the cells (positive control; maximal activation of NF-{kappa}B of the treated cells is usually observed after a few hours) showed maximal activation of NF-{kappa}B after 8 h without infection but the activity decreased sharply after 24 h and, to a marginal extent, after 48 h. When aspirin (0.1 or 2.0 mM) was added to infected HEp-2 cells, C. pneumoniae-induced NF-{kappa}B activation was inhibited to non-infected levels.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1. Effect of aspirin on activation of NF-{kappa}B as determined by relative luciferase activity in HEp-2 cells after infection with C. pneumoniae (filled bars) or without infection (control culture, open bars). TNF-{alpha} (10 ng ml-1) was added as a positive control without infection (shaded bars). Statistical significance of differences: *, P < 0.05; **, P < 0.01.

 

Induction of COX-2 by C. pneumoniae and its inhibition by aspirin

Since NF-{kappa}B is one of the controlling factors of COX-2 expression, we then determined COX-2 levels in C. pneumoniae-infected HEp-2 cells by immunoblotting (Fig. 2a). Amounts of COX-2 increased from 8 to 48 h after infection in a time-dependent manner compared with the basal level in non-infected cells. On the other hand, levels of the housekeeping COX-1 protein were not affected by chlamydial infection. Addition of aspirin (2 mM) partially decreased C. pneumoniae-induced COX-2 expression after 48 h of infection (Fig. 2b), possibly because COX-2 expression is activated by other transcription factors. Indomethacin had no effect on COX-2 expression (Fig. 2b).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2. (a) Immunoblot analysis of cyclo-oxygenases COX-2 and COX-1 in HEp-2 cells with and without C. pneumoniae (CP) infection. (b) Effects of aspirin (2 mM) and indomethacin (20 µM) on the induction of COX-2 at 48 h of C. pneumoniae infection. Similar results were obtained in several separate experiments.

 

PGE2 is produced in response to C. pneumoniae infection

At 8–48 h after C. pneumoniae infection, large amounts of PGE2 were produced in culture supernatants of the HEp-2 culture, peaking at 24 h (Fig. 3). Aspirin and indomethacin, both non-selective COX inhibitors, completely blocked the C. pneumoniae-induced production of PGE2 due to inhibition of COX-2 activity, although indomethacin inhibits the enzyme activity of COX-2 but not its expression, as shown in Fig. 2(b).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3. Production of PGE2 in culture supernatants of HEp-2 cells in the absence or presence of aspirin (2 mM) or indomethacin (20 µM). HEp-2 cells were grown in 24-well plates and infected with C. pneumoniae (CP). Aspirin or indomethacin was added immediately after infection. Data are shown as means ± SD of two separate experiments performed in triplicate.

 

NO production in HEp-2 cells after C. pneumoniae infection

Intriguingly, amounts of NO produced by C. pneumoniae-infected HEp-2 cells were essentially the same as those produced by non-infected cells, although HEp-2 cells that received a cytokine mixture containing TNF-{alpha}, IL-1ß and IFN-{gamma} showed increased NO (Table 1). TNF-{alpha} alone had no effect (data not shown). A larger inoculum of C. pneumoniae was toxic to host cells and was not tested for NO production.


View this table:
[in this window]
[in a new window]
 
Table 1. NO production by C. pneumoniae-infected and non-infected HEp-2 cells Results are NO (nitrite+nitrate) (µM) in culture supernatants, determined by HPLC. Data are presented as means ± SD of three separate experiments. For the C. pneumoniae-infected group, HEp-2 cells grown in 24-well plates were infected with C. pneumoniae at an m.o.i. of 0.4. For the ‘Cytokine mixture added’ group, non-infected HEp-2 cells were treated with a cytokine mixture containing 10 ng TNF-{alpha}, 1.0 ng IL-1ß and 100 U IFN-{gamma} ml-1.
 

Effects of aspirin on chlamydial growth

When HEp-2 cells were incubated for 48 h in the presence of aspirin, relative chlamydial growth, determined by the number of inclusion bodies, was 71.2 ± 4.8 % (mean ± SD) with 1.0 mM aspirin and 59.7 ± 5.1 % with 2.0 mM aspirin (Fig. 4a). In contrast, indomethacin did not affect chlamydial growth. A slight increase in chlamydial growth was observed at a low dose (0.1 mM) of aspirin. A high dose (2.0 mM) of aspirin not only decreased the numbers of inclusion bodies but also inhibited their enlargement (Fig. 4b, c). Thus, the mean diameter of 30 C. pneumoniae inclusion bodies chosen at random was 3.2 ± 0.4 µm in the presence of 2.0 mM aspirin and 5.4 ± 0.6 µm in its absence (significant difference, P < 0.01). Interestingly, the number of inclusion bodies in aspirin-treated cultures recovered to non-treated levels after incubation for 72 h, but the size of inclusion bodies remained the same (data not shown). The concentrations of aspirin used in these experiments were not toxic to the host cells under the conditions used; cell morphology remained normal and more than 95 % of the cells were viable after the aspirin treatment. However, 5.0 mM aspirin was cytotoxic to HEp-2 cells.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4. Effects of aspirin and indomethacin on chlamydial growth in HEp-2 cells. (a) Cells grown in 96-well plates were infected with C. pneumoniae and incubated with (filled bars) or without (open bar) aspirin or indomethacin. Staining was performed with mAb RR402. Staining with RR402 was comparable to that with genus-Chlamydia-specific mAb CF2. Relative chlamydial growth (%) of infected cells from drug-treated samples (filled bars) is expressed as means ± SD relative to the untreated control (open bar). Statistical significance: *, P < 0.05; **, P < 0.01 (versus non-treated control). (b)–(c) Immunofluorescence staining of C. pneumoniae J138 inclusion bodies in the absence (b) or presence (c) of 2 mM aspirin. HEp-2 cells were infected and incubated for 48 h. Bars, 10 µm.

 

EBs and HEp-2 cells were treated separately with 2 mM aspirin for 1 or 2 h, respectively, prior to infection. This treatment did not affect the subsequent growth of C. pneumoniae in HEp-2 cells in the presence or absence of 2 mM aspirin (data not shown), suggesting that aspirin inhibits proliferation of C. pneumoniae in host cells following infection.

Effect of tryptophan on aspirin-inhibited chlamydial growth

We found that the inhibition of chlamydial growth by high doses of aspirin was reversed by adding tryptophan to the culture medium in a dose-dependent manner; relative chlamydial growth, inhibited by 2 mM aspirin (59.7 ± 5.1 %), was increased to 75.3 ± 7.4 % with 10 µg tryptophan ml-1 and to almost 100 % with 100 µg tryptophan ml-1 (Fig. 5).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5. Effect of tryptophan on inhibition of chlamydial growth by aspirin. HEp-2 cells infected with C. pneumoniae were incubated with 2 mM aspirin in the absence or presence of 10 or 100 µg tryptophan ml-1 in the culture medium. Data are presented as means ± SD of five separate experiments. Statistical significance of differences: *, P < 0.01; **, P < 0.05.

 


    DISCUSSION
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
C. pneumoniae infection activates several signal transduction pathways in the host cell that trigger and/or enhance inflammatory reactions, and may act as a causative agent of atherosclerosis. Several studies, including this one, have shown that C. pneumoniae infection increases host-cell NF-{kappa}B activity (Krull et al., 1999; Matsushima et al., 1999; Dechend et al., 1999; Molestina et al., 2000). In this study, NF-{kappa}B activation was greater at 8 h after infection than at any other time, suggesting that some unknown mechanism(s) might inhibit NF-{kappa}B activation during the late phase of chlamydial growth or that C. pneumoniae growing in inclusion bodies does not affect the activation of NF-{kappa}B, although the infection might stimulate the activation system. We also demonstrated that aspirin at concentrations as low as 0.1 mM inhibited C. pneumoniae-induced NF-{kappa}B activation in HEp-2 cells. Since aspirin, a common anti-inflammatory agent, inhibits IKK-ß activity (Yin et al., 1998), we suggest that the activation of NF-{kappa}B by C. pneumoniae infection depends mainly on the activation of IKK-ß in HEp-2 cells. Another important finding of this study is that C. pneumoniae infection did not induce production of NO in HEp-2 cells, despite NF-{kappa}B activation. We reported previously that lymphotoxin inhibits C. pneumoniae growth in HEp-2 cells, possibly by NO production (Matsushima et al., 1999). NO has antimicrobial activity and transcription of the iNOS gene is regulated by NF-{kappa}B and AP-1 (Chu et al., 1998; Marks-Konczalik et al., 1998). It is plausible that C. pneumoniae may have a system to inhibit NO production by host cells so as to aid survival within infected cells.

Expression of COX-2 is induced by LPS (D'Acquisto et al., 1997), growth factors, cytokines and extracellular stimuli under the control of several transcriptional factors such as AP-2, SP-1 and NF-{kappa}B (Appleby et al., 1994; Pistritto et al., 1999). In this study, we found that C. pneumoniae infection induced COX-2 synthesis in HEp-2 cells, possibly through NF-{kappa}B activation, and this expression was partially inhibited by aspirin but not by indomethacin. C. pneumoniae infection enhances PGE2 production, which is completely blocked by aspirin and indomethacin by direct inhibition of COX-2 activity (Gierse et al., 1999). Prostaglandins of the E series, for example PGE2, are produced by the action of COX-2 on arachidonic acid liberated from membrane phospholipids. It has been demonstrated that PGE2 inhibits human T-cell proliferation (Goodwin et al., 1977) and also induces angiogenesis (He & Stuart, 1999). It has also been reported that COX-2 expression is increased in atherosclerotic plaques, predominantly in surrounding areas, in response to C. pneumoniae (Song et al., 2000). Our findings suggest that C. pneumoniae infection is involved in the progression of inflammatory responses through activation of NF-{kappa}B, which induces COX-2 and PGE2.

We also found that aspirin at high doses (1 and 2 mM) inhibited the formation of chlamydial inclusion bodies and proliferation of the bacterium within inclusion bodies in HEp-2 cells. These results suggest that the anti-chlamydial activity of aspirin might be associated with the inhibition of host-cell metabolism, including depletion of essential factors during chlamydial growth. Support for this assumption comes from the finding that the inhibition of chlamydial growth by aspirin was overcome when tryptophan was added to the culture medium. There was no significant effect of tryptophan addition alone on chlamydial growth (i.f.u.) in our culture system in the absence of aspirin (not shown). Tryptophan is an essential amino acid for chlamydiae and reduction of its availability might disturb various metabolic processes, depressing intracellular growth of the pathogen (Pantoja et al., 2000). It has been demonstrated recently that IFN-{gamma} restricts the growth of C. pneumoniae in HEp-2 cells through induction of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase, and the number of typical inclusion bodies decreased with an increase in smaller, less-dense, atypical inclusion bodies containing large, reticulate-like aberrant bodies (Pantoja et al., 2001). Further studies, including ultrastructural morphology of inclusion bodies and indoleamine 2,3-dioxygenase activity in aspirin-treated cells, should be carried out to determine whether the aspirin- and IFN-{gamma}-induced inhibition of C. pneumoniae growth is mediated through a common mechanism. It also remains to be clarified whether the inhibition of NF-{kappa}B pathways in the presence of aspirin is related to tryptophan catabolism and whether other mechanisms of tryptophan depletion, independent of NF-{kappa}B pathways, are responsible for the attenuation of chlamydial growth.

Very similar results describing the effect of aspirin on chlamydial growth and NF-{kappa}B activation by C. pneumoniae were published after our initial submission to the journal (Tiran et al., 2002). However, they did not demonstrate rescue from growth inhibition by tryptophan or investigate activation of COX-1 and -2 and PGE2 in response to infection by C. pneumoniae, all of which were demonstrated in this study. Our results suggest that C. pneumoniae, a possible pathogen involved in atherosclerosis, might trigger and/or enhance inflammatory reactions in atherosclerosis through NF-{kappa}B activation and they raise the possibility that aspirin therapy might be useful for C. pneumoniae infection in atherosclerosis, in addition to chemotherapy.


    Acknowledgments
 
We thank Ryutaro Fujinaga for his technical assistance and helpful suggestions. This study was supported by the Japan Society for the Promotion of Science, Research for the Future Program (JSPS-RETF 00L01411), a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI: 13226081, 14013043, 14021076, 14770063) and a research grant for Cardiovascular Diseases from the Ministry of Health, Labour, and Welfare (14kou-4).


    REFERENCES
 TOP
 Abstract
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  • Appleby, S. B., Ristimaki, A., Neilson, K., Narko, K. & Hla, T. (1994). Structure of the human cyclo-oxygenase-2 gene. Biochem J 302, 723–727.

  • Baeuerle, P. A. & Baltimore, D. (1988). I{kappa}B: a specific inhibitor of the NF-{kappa}B transcription factor. Science 242, 540–546.[Abstract/Free Full Text]

  • Baeuerle, P. A. & Henkel, T. (1994). Function and activation of NF-{kappa}B in the immune system. Annu Rev Immunol 12, 141–179.[Medline]

  • Brand, K., Page, S., Rogler, G. & 7 other authors (1996). Activated transcription factor nuclear factor-{kappa}B is present in the atherosclerotic lesion. J Clin Invest 97, 1715–1722.[Medline]

  • Budker, V., Gurevich, V., Hagstrom, J. E., Bortzov, F. & Wolff, J. A. (1996). pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nat Biotechnol 14, 760–764.[CrossRef][Medline]

  • Caldwell, H. D., Kromhout, J. & Schachter, J. (1981). Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 31, 1161–1176.[Abstract/Free Full Text]

  • Chu, S. C., Marks-Konczalik, J., Wu, H. P., Banks, T. C. & Moss, J. (1998). Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun 248, 871–878.[CrossRef][Medline]

  • Collins, T. (1993). Endothelial nuclear factor-{kappa}B and initiation of the atherosclerotic lesion. Lab Invest 68, 499–508.[Medline]

  • Cook, P. J., Honeybourne, D., Lip, G. Y., Beevers, D. G., Wise, R. & Davies, P. (1998). Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia. Stroke 29, 404–410.[Abstract/Free Full Text]

  • Cybulsky, M. I. & Gimbrone, M. A., Jr (1991). Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788–791.[Abstract/Free Full Text]

  • D'Acquisto, F., Iuvone, T., Rombola, L., Sautebin, L., Di Rosa, M. & Carnuccio, R. (1997). Involvement of NF-{kappa}B in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 418, 175–178.[CrossRef][Medline]

  • Dechend, R., Maass, M., Gieffers, J., Dietz, R., Scheidereit, C., Leutz, A. & Gulba, D. C. (1999). Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-{kappa}B and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100, 1369–1373.[Abstract/Free Full Text]

  • Dichtl, W., Nilsson, L., Goncalves, I., Ares, M. P., Banfi, C., Calara, F., Hamsten, A., Eriksson, P. & Nilsson, J. (1999). Very low-density lipoprotein activates nuclear factor-{kappa}B in endothelial cells. Circ Res 84, 1085–1094.[Abstract/Free Full Text]

  • Gawaz, M., Neumann, F. J., Dickfeld, T. & 8 other authors (1998). Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98, 1164–1171.[Abstract/Free Full Text]

  • Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K. & Isakson, P. C. (1999). Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 339, 607–614.

  • Goodwin, J. S., Bankhurst, A. D. & Messner, R. P. (1977). Suppression of human T-cell mitogenesis by prostaglandin.Existence of a prostaglandin-producing suppressor cell. J Exp Med 146, 1719–1734.[Abstract/Free Full Text]

  • Grayston, J. T. (1992). Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 15, 757–761.[Medline]

  • Grayston, J. T., Kuo, C. C., Wang, S. P. & Altman, J. (1986). A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 315, 161–168.[Abstract]

  • Grayston, J. T., Campbell, L. A., Kuo, C. C., Mordhorst, C. H., Saikku, P., Thom, D. H. & Wang, S. P. (1990). A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 161, 618–625.[Medline]

  • Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B. & Davis, R. J. (1996). Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15, 2760–2770.[Medline]

  • He, X. & Stuart, J. M. (1999). Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. J Immunol 163, 6173–6179.[Abstract/Free Full Text]

  • Jackson, L. A., Campbell, L. A., Kuo, C. C., Rodriguez, D. I., Lee, A. & Grayston, J. T. (1997). Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 176, 292–295.[Medline]

  • Kol, A., Bourcier, T., Lichtman, A. H. & Libby, P. (1999). Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103, 571–577.[Medline]

  • Kopp, E. & Ghosh, S. (1994). Inhibition of NF-{kappa}B by sodium salicylate and aspirin. Science 265, 956–959.[Abstract/Free Full Text]

  • Krull, M., Klucken, A. C., Wuppermann, F. N. & 7 other authors (1999). Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol 162, 4834–4841.[Abstract/Free Full Text]

  • Kuo, C. C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L. & Grayston, J. T. (1993). Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167, 841–849.[Medline]

  • Marks-Konczalik, J., Chu, S. C. & Moss, J. (1998). Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor {kappa}B-binding sites. J Biol Chem 273, 22201–22208.[Abstract/Free Full Text]

  • Matsushima, H., Shirai, M., Ouchi, K., Yamashita, K., Kakutani, T., Furukawa, S. & Nakazawa, T. (1999). Lymphotoxin inhibits Chlamydia pneumoniae growth in HEp-2 cells. Infect Immun 67, 3175–3179.[Abstract/Free Full Text]

  • Melnick, S. L., Shahar, E., Folsom, A. R., Grayston, J. T., Sorlie, P. D., Wang, S. P. & Szklo, M. (1993). Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 95, 499–504.[CrossRef][Medline]

  • Miyashita, N., Toyota, E., Sawayama, T. & Matsushima, T. (1998). An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan. Eur Heart J 19, 971. 971.

  • Molestina, R. E., Miller, R. D., Lentsch, A. B., Ramirez, J. A. & Summersgill, J. T. (2000). Requirement for NF-{kappa}B in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells. Infect Immun 68, 4282–4288.[Abstract/Free Full Text]

  • Neish, A. S., Williams, A. J., Palmer, H. J., Whitley, M. Z. & Collins, T. (1992). Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 176, 1583–1593.[Abstract/Free Full Text]

  • Ouchi, K., Fujii, B., Kanamoto, Y., Karita, M., Shirai, M. & Nakazawa, T. (1998). Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases. J Med Microbiol 47, 907–913.[Abstract]

  • Pantoja, L. G., Miller, R. D., Ramirez, J. A., Molestina, R. E. & Summersgill, J. T. (2000). Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2,3-dioxygenase activity. Infect Immun 68, 6478–6481.[Abstract/Free Full Text]

  • Pantoja, L. G., Miller, R. D., Ramirez, J. A., Molestina, R. E. & Summersgill, J. T. (2001). Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon. Infect Immun 69, 7927–7932.[Abstract/Free Full Text]

  • Pistritto, G., Franzese, O., Pozzoli, G., Mancuso, C., Tringali, G., Preziosi, P. & Navarra, P. (1999). Bacterial lipopolysaccharide increases prostaglandin production by rat astrocytes via inducible cyclo-oxygenase: evidence for the involvement of nuclear factor {kappa}B. Biochem Biophys Res Commun 263, 570–574.[CrossRef][Medline]

  • Poston, R. N., Haskard, D. O., Coucher, J. R., Gall, N. P. & Johnson-Tidey, R. R. (1992). Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140, 665–673.[Abstract]

  • Ramirez, J. A. (1996). Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 125, 979–982.[Abstract/Free Full Text]

  • Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801–809.[CrossRef][Medline]

  • Saikku, P., Leinonen, M., Mattila, K., Ekman, M. R., Nieminen, M. S., Makela, P. H., Huttunen, J. K. & Valtonen, V. (1988). Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet ii , 983–986.

  • Shaper, N. L., Hardiun-Lepers, A. & Shaper, J. H. (1994). Male germ cell expression of murine ß4-galactosyltransferase.A 796-base pair genomic region, containing two cAMP-responsive element (CRE)-like elements, mediates male germ cell-specific expression in transgenic mice. J Biol Chem 269, 25165–25171.[Abstract/Free Full Text]

  • Sharma, S. A., Tummuru, M. K. R., Blaser, M. J. & Kerr, L. D. (1998). Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-{kappa}B in gastric epithelial cells. J Immunol 160, 2401–2407.[Abstract/Free Full Text]

  • Shirai, M., Hirakawa, H., Kimoto, M. & 8 other authors (2000). Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. Nucleic Acids Res 28, 2311–2314.[Abstract/Free Full Text]

  • Shor, A., Kuo, C. C. & Patton, D. L. (1992). Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 82, 158–161.[Medline]

  • Siebenlist, U., Franzoso, G. & Brown, K. (1994). Structure, regulation and function of NF-{kappa}B. Annu Rev Cell Biol 10, 405–455.[CrossRef][Medline]

  • Song, Y. G., Kwon, H. M., Kim, J. M. & 10 other authors (2000). Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae. Yonsei Med J 41, 319–327.[Medline]

  • Speir, E., Yu, Z. X., Ferrans, V. J., Huang, E. S. & Epstein, S. E. (1998). Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 83, 210–216.[Abstract/Free Full Text]

  • Tiran, A., Gruber, H. J., Graier, W. F., Wagner, A. H., van Leeuwen, E. B. M. & Tiran, B. (2002). Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-{kappa}B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol 22, 1075–1080.[Abstract/Free Full Text]

  • Traenckner, E. B., Wilk, S. & Baeuerle, P. A. (1994). A proteasome inhibitor prevents activation of NF-{kappa}B and stabilizes a newly phosphorylated form of I{kappa}B-{alpha} that is still bound to NF-{kappa}B. EMBO J 13, 5433–5441.[Medline]

  • Wimmer, M. L. J., Sandmann-Strupp, R., Saikku, P. & Haberl, R. L. (1996). Association of chlamydial infection with cerebrovascular disease. Stroke 27, 2207–2210.[Abstract/Free Full Text]

  • Yamashita, K., Ouchi, K., Shirai, M., Gondo, T., Nakazawa, T. & Ito, H. (1998). Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29, 773–778.[Abstract/Free Full Text]

  • Yin, M. J., Yamamoto, Y. & Gaynor, R. B. (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I{kappa}B kinase-ß. Nature 396, 77–80.[CrossRef][Medline]




    This article has been cited by other articles:


    Home page
    DNA ResHome page
    K. Miura, H. Toh, H. Hirakawa, M. Sugii, M. Murata, K. Nakai, K. Tashiro, S. Kuhara, Y. Azuma, and M. Shirai
    Genome-wide Analysis of Chlamydophila pneumoniae Gene Expression at the Late Stage of Infection
    DNA Res, April 1, 2008; 15(2): 83 - 91.
    [Abstract] [Full Text] [PDF]


    Home page
    Infect. Immun.Home page
    E. Rydkina, A. Sahni, R. B. Baggs, D. J. Silverman, and S. K. Sahni
    Infection of Human Endothelial Cells with Spotted Fever Group Rickettsiae Stimulates Cyclooxygenase 2 Expression and Release of Vasoactive Prostaglandins
    Infect. Immun., September 1, 2006; 74(9): 5067 - 5074.
    [Abstract] [Full Text] [PDF]


    Home page
    Ann. N. Y. Acad. Sci.Home page
    S. K. SAHNI, E. RYDKINA, A. SAHNI, S. G. JOSHI, and D. J. SILVERMAN
    Potential Roles for Regulatory Oxygenases in Rickettsial Pathogenesis
    Ann. N.Y. Acad. Sci., December 1, 2005; 1063(1): 207 - 214.
    [Abstract] [Full Text] [PDF]


    Home page
    Infect. Immun.Home page
    D. R. Clifton, E. Rydkina, R. S. Freeman, and S. K. Sahni
    NF-{kappa}B Activation during Rickettsia rickettsii Infection of Endothelial Cells Involves the Activation of Catalytic I{kappa}B Kinases IKK{alpha} and IKK{beta} and Phosphorylation-Proteolysis of the Inhibitor Protein I{kappa}B{alpha}
    Infect. Immun., January 1, 2005; 73(1): 155 - 165.
    [Abstract] [Full Text] [PDF]


    Home page
    Antimicrob. Agents Chemother.Home page
    D. Caronzolo, V. Lucini, M. Pannacci, S. Grosso, F. Colleoni, F. Fraschini, and F. Scaglione
    Glucocorticoids Increase In Vitro and In Vivo Activities of Antibiotics against Chlamydophila pneumoniae
    Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4878 - 4881.
    [Abstract] [Full Text] [PDF]


    Home page
    Cancer Res.Home page
    F. Khwaja, J. Allen, J. Lynch, P. Andrews, and D. Djakiew
    Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75NTR Tumor Suppressor Protein
    Cancer Res., September 1, 2004; 64(17): 6207 - 6213.
    [Abstract] [Full Text] [PDF]


    Home page
    Infect. Immun.Home page
    J. Rodel, D. Prochnau, K. Prager, J. Baumert, K.-H. Schmidt, and E. Straube
    Chlamydia pneumoniae Decreases Smooth Muscle Cell Proliferation through Induction of Prostaglandin E2 Synthesis
    Infect. Immun., August 1, 2004; 72(8): 4900 - 4904.
    [Abstract] [Full Text] [PDF]


    This Article
    Right arrow Abstract Freely available
    Right arrow Full Text (PDF)
    Right arrow Alert me when this article is cited
    Right arrow Alert me if a correction is posted
    Right arrow Citation Map
    Services
    Right arrow Email this article to a friend
    Right arrow Similar articles in this journal
    Right arrow Similar articles in PubMed
    Right arrow Alert me to new issues of the journal
    Right arrow Download to citation manager
    Right arrow reprints & permissions
    Citing Articles
    Right arrow Citing Articles via HighWire
    Right arrow Citing Articles via CrossRef
    Right arrow Citing Articles via Google Scholar
    Google Scholar
    Right arrow Articles by Yoneda, H.
    Right arrow Articles by Shirai, M.
    Right arrow Search for Related Content
    PubMed
    Right arrow PubMed Citation
    Right arrow Articles by Yoneda, H.
    Right arrow Articles by Shirai, M.
    Agricola
    Right arrow Articles by Yoneda, H.
    Right arrow Articles by Shirai, M.


    HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
    INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS